热门资讯> 正文

Zenas BioPharma报告第二季度结果

2025-08-12 21:57

Zenas BioPharma, Inc. press release (NASDAQ:ZBIO): Q2 net loss of $52.2 million.
The company’s cash, cash equivalents and investments were $274.9 million.
The company expects that its cash, cash equivalents and investments, as of June 30, 2025, will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026.

More on Zenas BioPharma

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
Financial information for Zenas BioPharma, Inc.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。